| P50 | author | Attilio Guarini | Q56982241 |
| | Carla Minoia | Q58225752 |
| | Nicola Silvestris | Q87916808 |
| | Daniele Santini | Q37837892 |
| P2093 | author name string | Stefano Oliva | |
| | Angela Iacobazzi | |
| | Margherita Giannoccaro | |
| | Agnese Fioretti | |
| P2860 | cites work | Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium | Q28188767 |
| | Bradycardia due to anthracyclines | Q28327713 |
| | Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | Q32111479 |
| | Early and late arrhythmogenic effects of doxorubicin | Q33154962 |
| | Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism | Q33264052 |
| | Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma | Q33368803 |
| | Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention | Q33574045 |
| | Cardiotoxicity of the anticancer therapeutic agent bortezomib. | Q33882390 |
| | Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R | Q34249003 |
| | Thalidomide in cancer: potential uses and limitations | Q34299303 |
| | Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles | Q34403657 |
| | Complete atrioventricular block secondary to bortezomib use in multiple myeloma | Q34474586 |
| | Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease | Q35688733 |
| | Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management | Q35822612 |
| | Adverse effects of thalidomide administration in patients with neoplastic diseases | Q35909155 |
| | Effects of first-dose doxorubicin on cardiac rhythm as evaluated by continuous 24-hour monitoring. | Q53840944 |
| | Cardiac toxicity of high-dose chemotherapy | Q35949084 |
| | Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes | Q36891705 |
| | Thalidomide for treatment of multiple myeloma: 10 years later | Q37075738 |
| | Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib | Q37098098 |
| | New developments in anthracycline-induced cardiotoxicity. | Q37481832 |
| | Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management | Q37516733 |
| | Cardiotoxicity induced by tyrosine kinase inhibitors | Q37593059 |
| | Introducing a new entity: chemotherapy-induced arrhythmia. | Q37607920 |
| | Capecitabine-induced cardiotoxicity: case report and review of the literature | Q37697516 |
| | Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment | Q37807071 |
| | Cardiovascular effects of systemic cancer treatment | Q37815319 |
| | Symptomatic 5-fluorouracil-induced sinus bradycardia | Q37901554 |
| | Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study | Q41096827 |
| | The effects of adriamycin on normal and ouabain-toxic canine Purkinje and ventricular muscle fibers | Q41557812 |
| | Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature | Q41718741 |
| | Thalidomide-induced sinus bradycardia | Q42166156 |
| | Transient heart block. An unreported toxicity of high dose chemotherapy with cyclophosphamide and etoposide | Q42228655 |
| | Acquired episodic complete heart block after high-dose chemotherapy with cyclophosphamide and thiotepa | Q42284875 |
| | Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation | Q42437331 |
| | Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation | Q42513963 |
| | Evidence for sinoatrial blockade associated with high dose cytarabine therapy | Q42540816 |
| | Mitoxantrone-induced bradycardia | Q42550980 |
| | Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy | Q42555423 |
| | Fludarabine-induced bradycardia in a patient with refractory leukemia | Q42750097 |
| | Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina | Q43042597 |
| | Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib | Q43244803 |
| | Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma | Q43503967 |
| | Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines | Q43976448 |
| | Docetaxel with epirubicin--investigations on cardiac safety | Q44288946 |
| | Bradycardia during therapy for multiple myeloma with thalidomide | Q44842294 |
| | Sinusal bradycardia after receiving intermediate or high dose cytarabine: four cases from a single institution. | Q46016268 |
| | Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma | Q46329140 |
| | Doxorubicin-induced second degree and complete atrioventricular block | Q46476597 |
| | Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction | Q46581046 |
| | An evaluation of the cardiotoxicity of imatinib mesylate | Q46583056 |
| | Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma | Q46642466 |
| | The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. | Q46716138 |
| | High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation | Q46773001 |
| | NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity | Q46837798 |
| | Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil | Q46850749 |
| | Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 |
| | Nitrosomethylurea-Induced Lymphomas in Thymectomized Mice, in Relation to Thymus-Dependent and Independent Systems | Q53596232 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 739-751 | |
| P577 | publication date | 2012-07-13 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Antineoplastic drug-induced bradyarrhythmias | |
| P478 | volume | 11 | |